Evidence map›Paper›PMID 42518711›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2026

Visual Gains with Faricimab vs Aflibercept 8 mg in Naïve Retinovascular Disease: Global Real-World Cases and Literature Review.

Hana A Mansour, Chiara M Eandi, Francesco Pichi, Robert E Foster, Suzanne A Charbaji, Debdulal Chakraborty, Abdallah A Ellabban, Silvana Belotto, Hashem Abu Serhan, Simon Magnin and 28 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Hana A MansourDepartment of Ophthalmology (H.A.M., W.K., A.M.M.), American University of Beirut, Beirut, Lebanon.
Chiara M EandiHôpital Ophtalmique Jules-Gonin (C.H.E., S.M.), Fondation Asile des Aveugles, Lausanne, Switzerland.
Francesco PichiDepartment of Ophthalmology and Visual Sciences (F.P.), University of Toronto, Toronto, Canada.ORCID 0000-0002-7357-4166
Robert E FosterCincinnati Eye Institute (R.E.F.), Cincinnati, OH, USA.
Suzanne A CharbajiDepartment of Epidemiology and Population Health (S.A.C.), American University of Beirut, Beirut, Lebanon.
Debdulal ChakrabortyDisha Eye Hospital (D.C.), Silchar Medical College Sri Sankaradeva Nethralaya, Silchar, Assam, India.
Abdallah A EllabbanHull University Teaching Hospitals NHS Trust (A.A.E.), Hull, Yorkshire, UK.ORCID 0000-0002-6033-2969
Silvana BelottoCentro de Oftalmología Barraquer (S.B., S.A., M.J.C., S.V., J.E.), Barcelona, Spain.ORCID 0000-0002-8753-5635
Hashem Abu SerhanDepartment of Ophthalmology (H.A.S.), Hamad Medical Corporations, Doha, Qatar.ORCID 0000-0002-2953-2188
Simon MagninHôpital Ophtalmique Jules-Gonin (C.H.E., S.M.), Fondation Asile des Aveugles, Lausanne, Switzerland.
Lorenzo Lopez-GuajardoDepartment of Ophthalmology (L.L.G.), Hospital Clinico San Carlos, Madrid, Spain Profesor Asociado de Oftalmología, Universidad Complutense de Madrid, Madrid, Spain.
Eduardo Pérez-Salvador GarcíaServicio de Oftalmología del Hospital Universitario de Burgos (E.P.-S.G.), Burgos, Spain.ORCID 0000-0002-5340-8873
Stephen G SchwartzBascom Palmer Eye Institute (S.G.S.), University of Miami Miller School of Medicine, Miami, FL, USA.ORCID 0000-0002-1441-9473
Michael W StewartDepartment of Ophthalmology (M.W.S.), Mayo Clinic Florida, Jacksonville, FL, USA.
Amanda ReyInstitut Català de Retina (A.R., I.J.), Barcelona, Spain.
Ignasi JürgensInstitut Català de Retina (A.R., I.J.), Barcelona, Spain.ORCID 0000-0001-7168-7880
Antonio M B CasellaDepartment of Ophthalmology (A.M.B.C.), Universidade Estadual de Londrina, Londrina, Paraná, Brazil.ORCID 0000-0002-4552-2799
Anubhav UpadhyayASG Eye Hospitals (A.U.), Jaipur, Rajasthan, India.
Jay U ShethShantilal Shanghvi Eye Institute (J.U.S.), Mumbai, India.
Luiz H LimaDepartment of Ophthalmology and Visual Sciences (L.H.L., G.C.S.B.), Federal University of São Paulo, São Paulo, Brazil.ORCID 0000-0001-7304-909X
Suthasinee SinawatKKU Eye Center (S.S.), Department of Ophthalmology (S.S.), Khon Kaaen University, Bangkok, Thailand.ORCID 0000-0002-1998-333X
Santiago AbengoecheaCentro de Oftalmología Barraquer (S.B., S.A., M.J.C., S.V., J.E.), Barcelona, Spain.
Maria Jose CapellaCentro de Oftalmología Barraquer (S.B., S.A., M.J.C., S.V., J.E.), Barcelona, Spain.
Sonia Viver OllerCentro de Oftalmología Barraquer (S.B., S.A., M.J.C., S.V., J.E.), Barcelona, Spain.
Javier ElizaldeCentro de Oftalmología Barraquer (S.B., S.A., M.J.C., S.V., J.E.), Barcelona, Spain.
Wajiha J KheirDepartment of Ophthalmology (H.A.M., W.K., A.M.M.), American University of Beirut, Beirut, Lebanon.ORCID 0000-0002-4063-3860
Danny MammoCleveland Clinic Cole Eye Institute (D.A.M., G.C.S.B., N.M.), Cleveland, OH, USA.
Gabriel Castilho Sandoval BarbosaDepartment of Ophthalmology and Visual Sciences (L.H.L., G.C.S.B.), Federal University of São Paulo, São Paulo, Brazil.
Victor M VillegasDepartment of Ophthalmology (V.M.V.), University of Puerto Rico, San Juan, PR, USA.
Arjun DesaiASG Saatvik Eye Hospital (A.D.), Vadodara, India.
Koushik TripathyASG Hospitals (K.T.), Kolkata, India.
Suraj BalaCleveland Clinic Cole Eye Institute (D.A.M., G.C.S.B., N.M.), Cleveland, OH, USA.
Nitesh MohanCleveland Clinic Cole Eye Institute (D.A.M., G.C.S.B., N.M.), Cleveland, OH, USA.
Ayman G ElnahryDepartment of Ophthalmology and Visual Sciences (A.E.), School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0000-0001-5148-316X
Sami H UwaydatJones Eye Institute (S.H.U.), University of Arkansas, Little Rock, AR, USA.
Daniel G CherfanBeirut Eye Specialty Hospital (D.G.C.), Beirut, Lebanon.
Maurizio Battaglia ParodiDepartment of Ophthalmology (M.B.P.), University Vita-Salute Milan, Milan, Italy.
Ahmad M MansourDepartment of Ophthalmology (H.A.M., W.K., A.M.M.), American University of Beirut, Beirut, Lebanon.ORCID 0000-0001-8430-2214

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To compare the visual gains of faricimab and aflibercept 8 mg as first-line in real-world management of retinovascular diseases. Methods: Retrospective multicenter interventional case series with retinovascular diseases initiated on faricimab or aflibercept 8 mg till August 30, 2025. Main outcome measure was visual gain in logMAR. Linear mixed-effects model was used to compare vision increase between the two drug groups. In addition, comparative Phase 3 trials were supplemented by a literature review of treatment-naïve eyes using major databases till September 30, 2025. Results: We collected 500 treated eyes from 35 collaborating centers. The treatment groups included 395 eyes receiving faricimab vs 105 receiving aflibercept 8 mg distributed into neovascular macular degeneration (270 vs 58), diabetic macular edema (97 vs 39) and macular edema associated with retinal vein occlusion (28 vs 8). Adjusted visual gains were comparable between the two drugs in various retinal categories (p=0.672). Conclusion: Visual acuity improved significantly and equally in both aflibercept 8 mg and faricimab in several treatment-naïve retinovascular diseases.

Indexed as

aflibercept 8 mgdiabetic maculopathyfaricimabmacular degenerationretinal vein occlusion

Identifiers

PMID42518711
PMCPMC13382612

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.